3 Jesús F Bermejo-Martin^{1,2,3}*, Milagros González-Rivera^{4,5}*, Raquel Almansa^{1,2,3}*, Dariela

4 Micheloud^{6*}, Ana P. Tedim^{1,2*}, Marta Domínguez-Gil^{7*}, Salvador Resino^{8*}, Marta

5 Martín-Fernández^{1,2}, Pablo Ryan Murua⁹, Felipe Pérez-García¹⁰, Luis Tamayo^{1,11}, Raúl

6 Lopez-Izquierdo¹², Elena Bustamante¹³, César Aldecoa^{1,14,15}, José Manuel Gómez¹⁶, Jesús

7 Rico-Feijoo^{1,15}, Antonio Orduña¹⁷, Raúl Méndez¹⁸, Isabel Fernández Natal¹⁹, Gregoria

8 Megías²⁰, Montserrat González-Estecha^{4,5}, Demetrio Carriedo²¹, Cristina Doncel ^{1,2,3},

9 Noelia Jorge ^{1,2,3}, Alicia Ortega^{1,2,3}, Amanda de la Fuente^{1,2,3}, Félix del Campo²², José

10 Antonio Fernández-Ratero²³, Wysali Trapiello ²⁴, Paula González-Jiménez¹⁸, Guadalupe

11 Ruiz²⁴, Alyson A. Kelvin^{25,26}, Ali Toloue Ostadgavahi^{25,26}, Ruth Oneizat⁷, Luz María

12 Ruiz⁷, Iria Miguéns⁶, Esther Gargallo⁶, Ioana Muñoz⁶, Sara Pelegrin¹⁵, Silvia Martín^{1,15},

13 Pablo García Olivares¹⁶, Jamil Antonio Cedeño¹⁶, Tomás Ruiz Albi²², Carolina Puertas⁴,

14 Jose Ángel Berezo^{1,11}, Gloria Renedo¹³, Rubén Herrán^{1,11}, Juan Bustamante-Munguira²⁷,

15 Pedro Enríquez¹¹, Ramón Cicuendez¹³, Jesús Blanco¹¹, Jesica Abadia²⁸, Julia Gómez

16 Barquero²⁸, Nuria Mamolar¹³, Natalia Blanca-López⁹, Luis Jorge Valdivia²¹, Belén

17 Fernández Caso¹⁹, María Ángeles Mantecón²⁰, Anna Motos^{3,29}, Laia Fernandez-Barat ^{3,29},

18 Ricard Ferrer^{3,30}, Ferrán Barbé^{3,31}, Antoni Torres^{3,29 \(\Delta \)}, Rosario Menéndez^{3,18 \(\Delta \)}, José María

19 Eiros^{7 Δ}, David J Kelvin^{Δ} 25,26.

20 * These authors contributed equally

21 ^Δ These authors contributed equally

- 23 1. Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación
- 24 Biomédica de Salamanca, (IBSAL), Paseo de San Vicente, 58-182, 37007 Salamanca,
- 25 Spain
- 26 2. Hospital Universitario Río Hortega, Calle Dulzaina, 2, 47012 Valladolid, Spain.
- 27 3. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES),
- 28 Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain
- 29 4. Department of Laboratory Medicine, Hospital General Universitario Gregorio Marañón,
- 30 Calle del Dr. Esquerdo, 46, 28007 Madrid, Spain.
- 31 5. Department of Medicine, Faculty of Medicine, Universidad Complutense de Madrid,
- 32 Plaza de Ramón y Cajal, s/n, 28040 Madrid, Spain.
- 33 6. Emergency Department, Hospital General Universitario Gregorio Marañón, Calle del
- 34 Dr. Esquerdo, 46, 28007 Madrid, Spain.
- 35 7. Microbiology Service, Hospital Universitario Rio Hortega, Calle Dulzaina, 2, 47012
- 36 Valladolid, Spain
- 37 8. Viral Infection and Immunity Unit, Centro Nacional de Microbiología, Instituto de
- 38 Salud Carlos III, Ctra. de Pozuelo, 28, 28222 Majadahonda, Spain
- 39 9. Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain
- 40 10. Servicio de Microbiología Clínica, Hospital Universitario Príncipe de Asturias, Carr.
- 41 de Alcalá, s/n, 28805, Madrid, Spain
- 42 11. Intensive Care Unit, Hospital Universitario Rio Hortega, Calle Dulzaina, 2, 47012
- 43 Valladolid, Spain.

- 44 12. Emergency Department, Hospital Universitario Rio Hortega, Calle Dulzaina, 2, 47012
- 45 Valladolid, Spain.
- 46 13. Intensive Care Unit, Hospital Clínico Universitario de Valladolid. Av. Ramón y Cajal,
- 47 3, 47003 Valladolid, Spain
- 48 14. Department of Anesthesiology, Facultad de Medicina de Valladolid, Av. Ramón y
- 49 Cajal, 7, 47005 Valladolid, Spain.
- 50 15. Anesthesiology and Reanimation Service, Hospital Universitario Rio Hortega, Calle
- 51 Dulzaina, 2, 47012 Valladolid, Spain.
- 52 16. Intensive Care Unit. Hospital General Universitario Gregorio Marañón. Calle del Dr.
- 53 Esquerdo, 46, 28007 Madrid, Spain.
- 54 17. Microbiology Service, Hospital Clinico Universitario de Valladolid, Av. Ramón y
- 55 Cajal, 3, 47003 Valladolid, Spain.
- 56 18. Pulmonology Service, Hospital Universitario y Politécnico de La Fe, Avinguda de
- 57 Fernando Abril Martorell, 106, 46026, Valencia Spain
- 58 19. Clinical Microbiology Department. Complejo Asistencial Universitario de León. Calle
- 59 Altos de nava, s/n, 24001 León, Spain.
- 60 20. Microbiology Service, Hospital Universitario de Burgos, Av. Islas Baleares, 3, 09006
- 61 Burgos, Spain
- 62 21. Intensive Care Unit. Complejo Asistencial Universitario de León. Calle Altos de nava,
- 63 s/n, 24001 León, Spain.
- 64 22. Pneumology Service, Hospital Universitario Río Hortega / Biomedical Engineering
- 65 Group, Universidad de Valladolid, Calle Dulzaina, 2, 47012 Valladolid, Spain.

- 66 23. Intensive Care Unit. Hospital Universitario de Burgos, Av. Islas Baleares, 3, 09006 67 Burgos, Spain.
- 68 24. Clinical Analysis Service. Hospital Clínico Universitario de Valladolid, Av. Ramón y 69 Cajal, 3, 47003 Valladolid, Spain
- 70 25. Department of Microbiology and Immunology, Faculty of Medicine, Canadian Center 71 for Vaccinology CCfV, Dalhousie University, Halifax, Nova Scotia, B3H 4R2, Canada 72 26. Laboratory of Immunity, Shantou University Medical College, 22 Xinling Rd, Jinping,
- 73 Shantou, Guangdong, China.
- 74 27. Department of Cardiovascular Surgery, Hospital Clínico Universitario de Valladolid. 75 Av. Ramón y Cajal, 3, 47003 Valladolid, Spain
- 76 28. Infectious diseases clinic, Internal Medicine Department, Hospital Universitario Río 77 Hortega, Valladolid, Calle Dulzaina, 2, 47012 Valladolid, Spain
- 78 29. Department of Pulmonology, Hospital Clinic de Barcelona, Universidad de Barcelona, 79 Institut D investigacions August Pi I Sunyer (IDIBAPS), Carrer del Rosselló, 149, 08036 80 Barcelona, Spain.
- 81 30. Intensive Care Department, Vall d'Hebron Hospital Universitari. SODIR Research 82 Group, Vall d'Hebron Institut de Recerca, Passeig de la Vall d'Hebron, 119, 08035 83 Barcelona, Spain.
- 84 31. Respiratory Department, Institut Ricerca Biomedica de Lleida, Av. Alcalde Rovira 85 Roure, 80, 25198 Lleida, Spain.
- 86 Corresponding author: David J Kelvin Department of Microbiology and Immunology, 87 Dalhousie University, Halifax, Nova Scotia, B3H 4R2, Canada. E-mail address: 88 dkelvin@jidc.org.

90 Background: COVID-19 can course with respiratory and extrapulmonary disease. SARS-91 CoV-2 RNA is detected in respiratory samples but also in blood, stool and urine. Severe 92 COVID-19 is characterised by a dysregulated host response to this virus. We studied 93 whether viral RNAemia or viral RNA load in plasma are associated to severe COVID-19 94 and also to this dysregulated response. 95 Methods: 250 patients with COVID-19 were recruited (50 outpatients, 100 hospitalised 96 ward patients, and 100 critically ill). Viral RNA detection and quantification in plasma was 97 performed using droplet digital PCR, targeting the N1 and N2 regions of the SARS-CoV-2 98 nucleoprotein gene. The association between SARS-CoV-2 RNAemia and viral RNA load 99 in plasma with severity was evaluated by multivariate logistic regression. Correlations 100 between viral RNA load and biomarkers evidencing dysregulation of host response were 101 evaluated by calculating the Spearman correlation coefficients. 102 **Results:** the frequency of viral RNAemia was higher in the critically ill patients (78%) 103 compared to ward patients (27%) and outpatients (2%) (p<0.001). Critical patients had 104 higher viral RNA loads in plasma than non-critically ill patients, with non survivors 105 showing the highest values. When outpatients and ward patients were compared, viral 106 RNAemia did not show significant associations in the multivariate analysis. In contrast, 107 when ward patients were compared with ICU patients, both viral RNAemia and viral RNA 108 load in plasma were associated with critical illness (OR [CI 95%], p): RNAemia (3.92 109 [1.183 - 12.968], 0.025), viral RNA load (N1) (1.962 [1.244 - 3.096], 0.004); viral RNA 110 load (N2) (2.229 [1.382 - 3.595], 0.001). Viral RNA load in plasma correlated with higher 111 levels of chemokines (CXCL10, CCL2), biomarkers indicative of a systemic inflammatory 112 response (IL-6, CRP, Ferritin), activation of NK cells (IL-15), endothelial dysfunction

113 (VCAM-1, angiopoietin-2, ICAM-1), coagulation activation (D-Dimer and INR), tissue

114 damage (LDH, GPT), neutrophil response (neutrophils counts, myeloperoxidase, GM-115 CSF) and immunodepression (PD-L1, IL-10, lymphopenia and monocytopenia). 116 Conclusions: SARS-CoV-2 RNAemia and viral RNA load in plasma are associated to 117 critical illness in COVID-19. Viral RNA load in plasma correlates with key signatures of 118 dysregulated host responses, suggesting a major role of uncontrolled viral replication in the 119 pathogenesis of this disease. 120 Key words: SARS-CoV-2, cytokine, sepsis, COVID-19, plasma, RNAemia, viral RNA 121 load, ICU

140 With well over 43 million cases and 1.56212 deaths globally, Coronavirus disease 2019 141 (COVID-19) has become the top economic and health priority worldwide [1]. Among 142 hospitalized patients, around 10–20% are admitted to the intensive care unit (ICU), 3–10% 143 require intubation and 2-5% die [2]. SARS-CoV-2 RNA is commonly detected in 144 nasopharyngeal swabs; however viral RNA can be found in sputum, lung samples, 145 peripheral blood, serum, stool samples, and to a limited extent urine [3] [4] [5] [6]. While 146 the lungs are most often affected, severe COVID-19 also induce inflammatory cell 147 infiltration, haemorrhage, and degeneration or necrosis in extra-pulmonary organs (spleen, 148 lymph nodes, kidney, liver, central nervous system) [7] [8]. Patients with severe COVID-149 19 show signatures of dysregulated response to infection, with immunological alterations 150 involving moderate elevation of some cytokines and chemokines such as IL-6, IL-10 or 151 CXCL10, deep lymphopenia with neutrophilia, systemic inflammation (elevation of C 152 Reactive Protein, ferritin), endothelial dysfunction, coagulation hyper-activation (D-153 dimers) and tissue damage (LDH) [9] [10] [11] [12] [13] [14]. 154 Our hypothesis is that systemic distribution of the virus or viral components could be 155 associated to the severity of COVID-19, and, in turn to a number of parameters indicating 156 the presence of a dysregulated response to the infection. 157 While the SARS-CoV-2 virus has been reported to be difficult to culture from blood [4], 158 PCR based methods are able to detect and quantify the presence of genomic material of the 159 virus in serum or plasma, representing an useful approach to evaluate the impact of the 160 extrapulmonary dissemination of viral material on disease severity and also on the host

161 response to the infection [5] [15]. An excellent approach for achieving absolute

162 quantification of viral RNA load is droplet digital PCR (ddPCR). ddPCR is a next-

163 generation PCR method, which offers absolute quantification with no need of standard 164 curve and greater precision and reproducibility than currently available qRT-PCR methods, 165 as revised elsewhere [16].

166 We employed here ddPCR to detect and quantify viral RNA in plasma from COVID-19 167 patients discharged from the emergency room with mild severity, patients admitted to the 168 ward with moderate severity, and critically ill patients. Our objectives in this study were: 169 1) to evaluate if there is an association between SARS-CoV-2 RNAemia and viral RNA 170 load with moderate disease; 2) to evaluate if there is an association between SARS-CoV-2 171 RNAemia and viral RNA load with critical illness; 3) to evaluate the correlations between 172 SARS-CoV-2 RNA load in plasma and parameters of dysregulated host responses against 173 SARS-CoV-2.

174

175

176

177

178

179

180

181

182

184 Methods

185 Study design: 250 adult patients with a positive nasopharyngeal swab polymerase chain 186 reaction (PCR) test for SARS-CoV-2 performed at participating hospitals were recruited 187 during the first pandemic wave in Spain from March 16th to the 15th of April 2020. The 188 patients recruited were of three different categories. The first corresponded to patients 189 examined at an emergency room and discharged within the first 24 hours (outpatients 190 group, n=50). The second group were patients hospitalized to pneumology, infectious 191 diseases or internal medicine wards (wards group, n=100). Patients who required critical 192 care or died during hospitalization were excluded from this group, in order to have a group 193 of clear moderate severity. The third group corresponded to patients admitted to the ICU 194 (n=100). Patient's recruited by participating hospital are detailed in the additional file 1. 195 20 healthy blood donors were included as controls. These controls were recruited during 196 the pandemics, in parallel to the SARS-CoV-2 infected patients, and were negative for 197 SARS-CoV-2 IgG. This study was registered at Clinicaltrials.gov with the identification 198 NCT04457505.

199 Blood samples: Plasma from blood collected in EDTA tubes samples was obtained from 200 the three groups of patients in the first 24 hours following admission to the emergency 201 room, to the ward, or to the ICU, at a median collection day since disease onset of 7, 8 and 202 10 respectively, and also. from 20 blood donors (10 men and 10 women).

203 **Biomarker profiling:** a panel of biomarkers was profiled by using the Ella-SimplePlexTM 204 immunoassay (San Jose, California, U.S.A), informing of the following biological 205 functions potentially altered in severe COVID-19, based in the available evidence on 206 COVID-19 physiopathology [13] [17] and also in our previous experience on emerging 207 infections and sepsis [18] [19] [20] [21]: neutrophil degranulation: Lipocalin-2/NGAL, 208 myeloperoxidase; endothelial dysfunction: ICAM-1, VCAM-1/CD106, Angiopoietin 2; T

209 cell survival and function: IL-7, Granzyme B; immunosuppression: IL-1ra, B7-H1/PD-L1, 210 IL-10; chemotaxis: CXCL10/IP10, CCL2; Th1 response: Interleukin 1 beta, IFN-γ, IL-211 12p70, IL-15, TNF-α, IL-2; Th2 response: IL-4, IL-10; Th17 response: IL-6, IL-17A; 212 granulocyte mobilization / activation: G-CSF, GM-CSF; coagulation activation: D-Dimer; 213 acute phase reactants: Ferritin (C Reactive protein and LDH were profiled in each 214 participant hospital by their central laboratories).

215 Detection and quantification of SARS-CoV-2 RNA in plasma: RNA was extracted from 216 100 µl of plasma using an automated system, eMAG® from bioMérieux® (Marcy l'Etoile, 217 France). Detection and quantification of SARS-CoV-2 RNA was performed in five µl of 218 the eluted solution using the Bio-Rad SARS-CoV-2 ddPCR kit according to 219 manufacturer's specifications on a QX-200 droplet digital PCR platform from the same 220 provider. This PCR targets the N1 and N2 regions of the viral nucleoprotein gene and also 221 the human ribonuclease (RNase) P gene using the primers and probes sets detailed in the 222 CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel [22]. 223 Samples were considered positive for SARS-CoV-2 when N1 and/or N2 presented values $224 \ge 0.1$ copies/ μ L in a given reaction. RNase P gene was considered positive when it 225 presented values ≥ 0.2 copies/ μ L, following manufacturer's indications. The test was only 226 considered valid when RNase P gene was positive. Final results were given in copies of 227 cDNA / mL of plasma. IgG specific for the Nucleocapsid Protein of SARS-CoV-2 was 228 detected in 150 µl of plasma using the Abbott Architect SARS-CoV-2 IgG Assay (Illinois, 229 U.S.A). Viral RNA and SARS-CoV-2 IgG were profiled in the same plasma sample. 230 Statistical analysis: For the demographic and clinical characteristics of the patients, the 231 differences between groups were assessed using the Chi-square test / Fisher's Exact Test 232 where appropriated for categorical variables. Differences for continuous variables were 233 assessed by using the Kruskal-Wallis test with post hoc tests adjusting for multiple

234 comparisons. Multivariate logistic regression analysis was employed to evaluate the 235 association between viral RNAemia and viral RNA load in plasma with severity, in the 236 comparisons [outpatients vs ward patients] and [ward patients vs ICU patients]. Variables 237 showing significant differences between groups in each comparison in the Kruskal-Wallis 238 test were further introduced in the multivariate analysis as adjusting variables. The list of 239 variables considered as potential adjusting variables were [Age (years)], [Sex (male)], 240 [Alcoholism], [Smoker], [Drug abuse], [Cardiac disease], [Chronic vascular disease], 241 [COPD], [Asthma], [Obesity], [Hypertension], [Dyslipidemia], [Chronic renal disease], 242 [Chronic hepatic disease], [Neurological disease], [HIV], [Autoimmune disease], [Chronic 243 inflammatory bowel disease], [Type 1 diabetes], [Type 2 diabetes], [Cancer], [Invasive 244 mechanical ventilation], [Non-invasive mechanical ventilation], [SARS-CoV-2 IgG], 245 [Temperature (°C)], [Systolic Pressure (mmHg)], [Oxygen saturation (%)], [Bilateral 246 pulmonary infiltrate], [Glucose (mg/dl)], [Creatinine (mg/dl)], [Na (mEq/L)], [K 247 (mEq/L)], [Platelets (cell x $10^3 / \mu l$)], [INR], [D Dimer (pg/ml)], [LDH (UI/L)], [GPT 248 (UI/L)], [Ferritin (pg/ml)], [CRP (mg/dl)], [Haematocrit (%)], [Lymphocytes (cells/mm3)], 249 [Neutrophils (cells/mm3)], [Monocytes (cells/mm3)]. Multivariate logistic regression 250 analysis was performed using the "Enter" method, but also the backward stepwise 251 selection method (Likelihood Ratio) was employed in each case to confirm the association 252 between viral RNAemia and viral RNA load in plasma with disease severity (pin < 0.05, 253 pout < 0.10), not forcing entry of these variables in the model. Correlation analysis were 254 performed using the Spearman test applying the Bonferroni correction of the p value. 255 Variables evaluated for correlation with viral RNA load were: [Temperature (°C)], 256 [Systolic Pressure (mmHg)], [Oxygen saturation (%)], [Lymphocytes (cells/mm3)], 257 [Neutrophils (cells/mm3)], [Monocytes (cells/mm3)], [Creatinine (mg/dl)], [LDH (UI/L)], 258 [GPT (UI/L)], [Platelets (cell x 10³ / μl)], [INR], [CRP (mg/dl)], and all the biomarkers

259 analyzed by Ella- SimplePlex. Statistical analysis was performed with IBM SPSS® version 260 20 (IBM, Armonk, New York, USA).

261 Results

262 Clinical characteristics of the patients (Table 1): Patients requiring hospitalization 263 (either general ward or ICU) were older than those patients discharged to their home from 264 the ER. Critically ill patients were more frequently male than those in the other groups. 265 Comorbidities of obesity, hypertension, dyslipidemia and type 2 diabetes were more 266 commonly found in patients requiring hospitalization, with no significant differences found 267 in the comorbidities profile between critically ill and non-critically ill hospitalized patients. 268 14% of the patients in clinical wards required non-invasive mechanical ventilation, while 269 96% of the patients admitted to the ICU required invasive mechanical ventilation. 270 Critically ill patients had increased glucose levels, along with higher concentration of 271 neutrophils in blood, increased levels of ferritin and C-reactive protein (denoting activation 272 of the systemic inflammatory response). Increased levels of INR and D-dimers (reflecting 273 activation of the coagulation system), as well as LDH and GPT, which levels raise as 274 consequence of tissue and liver damage, were also observed in critically ill patients. 275 Patients admitted to the ICU also showed a lower haematocrit, pronounced lymphopenia 276 and lower monocyte counts at admission. ICU patients stayed longer in the hospital than 277 ward patients, with 49 % having a fatal outcome.

278 Viral RNAemia, viral RNA load in plasma and specific SARS-Cov-2 IgG in the three 279 groups of patients. As depicted in table 1, the frequency of the detection of SARS-CoV-2 280 viral RNA (RNAemia) was significantly higher in the critically ill patients (78%) 281 compared to ward patients (27%) and outpatients (2%) (p<0.001). Similarly, the group of 282 critically patients showed higher viral RNA loads in plasma than either ward or outpatients 283 (p<0.001) (Table 1 and Figure 1). Non survivors showed the highest concentrations of viral 284 RNA in plasma: viral RNA load (N1 region) in ICU non survivors: 1587 copies / ml 285 [10248]; viral RNA load (N1 region) in ICU survivors 574 copies / mL [1872] (results 286 expressed as median [interquartile rank]); viral RNA load (N2 region) in ICU non 287 survivors: 2798 copies / ml [12012]; viral RNA load (N2 region) in ICU survivors 523 288 copies / mL [1478]. Patients admitted to the wards showed a significant higher frequency 289 of viral RNAemia than outpatients, but viral RNA loads were not significantly different 290 with the latter group (Table 1 and Figure 1). Critically ill patients also had a higher 291 frequency of specific SARS-CoV-2 IgG responses than the other groups (70% in ICU 292 compared to 52% and 49% in the outpatients and ward groups, p < 0.05, table 1). No 293 significant differences were found between the group of outpatients and those admitted to 294 the ward. The prevalence of viral RNAemia did not differ between those patients testing 295 positive and those testing negative for SARS-CoV-2 IgG (43.8 % and 40.4 % respectively, 296 p = 0.586), who in addition showed no differences in viral RNA load (data not shown). 297 Patients with viral RNAemia showed no differences in the days since onset of symptoms 298 compared to those with no viral RNAemia (8.0 days [6.0]; 8.0 days [7.2], p = 0.965). In 299 contrast, samples from patients with SARS-CoV-2 IgG were collected later since disease 300 onset that those without SARS-CoV-2 IgG (10.0 days [7]; 7.0 days [6.0], p = 0.003) 301 Multivariate analysis to evaluate the association between viral RNAemia and viral 302 RNA load in plasma with moderate disease and critical illness. While the proportion of 303 patients with viral RNAemia was higher in the wards group compared to the outpatients' 304 group (table 1), the multivariate analysis did not show a significant association between the 305 presence of viral RNAemia and being hospitalised at the ward, with none of the both 306 methods employed (Additional files 2 and 3). In contrast, when the ward group was 307 compared with critically ill patients, a significant direct association was found between

308 viral RNAemia and viral RNA load in critically ill patients, using the "Enter" method 309 (Table 2) but also the backward stepwise selection method (additional file 4).

310 Correlations between viral RNA load in plasma and biological responses to SARS-311 CoV-2 infection: viral RNA load in plasma (targeting either the N1 and the N2 regions)
312 showed the strongest direct correlations with plasma levels of CXCL10, LDH, IL-10, IL-6,
313 IL-15, myeloperoxidase and CCL-2 (MCP-1) and inverse correlations with lymphocytes,
314 monocytes and O2 saturation (Figure 2). These were the parameters whose levels varied
315 the most in critically patients compared with ward and outpatient groups (Figures 3 and 4
316 and additional file 5). CXCL10 was the most accurate identifier of viral RNAemia in
317 plasma (area under the curve (AUC), [CI95%], p) = 0.85 [0.80 – 0.89), <0.001), and IL-15
318 was the cytokine which most accurately differentiated clinical ward patients from ICU
319 patients (AUC: 0.82 [0.76 – 0.88], <0.001). Plasma viral RNA load also showed significant
320 direct correlations with levels of VCAM-1, PDL-1, GM-CSF, G-CSF, neutrophil counts,
321 IL-1ra, CRP, INR, D-dimer, TFNα, Angiopoietin-2, GPT, ICAM-1, IL-7 and Ferritin
322 (Figure 2), with most of these mediators showing the highest variations in the critically ill
323 patients (Figures 3 and 4 and additional file 5).

324 Discussion

325 Our study demonstrates that the presence of SARS-CoV-2-RNA in plasma is associated to 326 critical illness in COVID-19 patients, with the strength of association being the highest in 327 those patients with the highest viral RNA loads. This association was independent of other 328 factors also related to disease severity. Moreover, those critically ill patients who died 329 presented with higher viral RNA loads in plasma than those who survived. SARS-CoV-2 330 viral RNA was detected in the plasma of the vast majority of those COVID-19 patients 331 admitted to the ICU (78%). As far as we know, our study is the largest one to date using 332 ddPCR to quantify SARS-CoV-2 RNA load in plasma from COVID-19 patients, and the

333 only one with a multicentric design. Our results are in consonance with those from Veyer 334 et al, who, in a pilot study using this technology, found higher viral RNA loads and a 335 prevalence of RNA viremia of 88% in twenty six COVID-19 patients who were critically 336 ill [16]. The results are also in agreement with those of Hagman et al, who, using standard 337 RT-PCR technology, found that the presence of SARS-CoV-2 RNA in serum at hospital 338 admission was associated with a seven-fold increased risk of critical disease and an eight-339 fold increased risk of death in a cohort of 167 patients hospitalised for COVID-19 [23]. 340 Although our study did not determine if the presence of viral RNA in plasma reflects the 341 presence of live virus in peripheral blood, the association found between the presence and 342 concentration of viral RNA in plasma and critical illness suggests that viral replication is 343 more robust in severe COVID-19, and/or that critically ill patients with this disease are not 344 able to control viral replication. This notion is further supported by the correlations found 345 in our study between viral RNA load in plasma and hypercytokinemia involving CXCL10, 346 IL-10, CCL2, IL-6 and IL-15, where the levels of these cytokines were the highest in 347 patients with critical illness. The correlation between viral RNA load and higher levels of 348 cytokines has also been described in the severe infections caused by H5N1 and pandemic 349 H1N1 influenza strains [24] [25]. Active viral replication stimulates the secretion of 350 cytokines by the recognition of viral RNA by endosomal receptors such as toll like 351 receptor 7 (TLR7) in human plasmacytoid dendritic cells and B cells, or TLR8 in myeloid 352 cells [26]. While the elevation of CXCL10, IL-10, CCL2, IL-6 has been extensively 353 documented in severe COVID-19 [9] [10], our work demonstrates a clear correlation 354 between these cytokines and plasma viral load. Furthermore, we report for the first time a 355 major role of IL-15 in severe COVID-19. High levels of IL-15 in critically ill patients with 356 high SARS-CoV-2 RNA load in plasma could be an attempt to stimulate Natural Killer 357 cells to fight the virus [27]. We previously demonstrated that high levels of IL-15, along

358 with IL-6, constituted a signature of critical illness in H1N1 pandemic influenza infection 359 [20].

360 Viral RNA load correlated with higher levels of myeloperoxidase in plasma, which were 361 the highest in those patients admitted to the ICU. This is a marker of neutrophil 362 degranulation and a potent tissue damage factor which has been proposed to play a role in 363 the pathogenesis of ARDS secondary to influenza, by mediating claudin alteration on 364 endothelial tight junctions, eventually leading to protein leakage and viral spread [28]. In 365 this regard, the correlation found between viral RNA load in plasma and higher levels of 366 LDH and GPT could suggest a direct or indirect role of viral replication in mediating tissue 367 destruction in COVID-19.

368 Interesting, but less robust, direct correlations were found between viral RNA load in 369 plasma with GM-CSF and neutrophil counts in blood, further reinforcing the role of 370 neutrophil mediated responses in the pathogenesis of severe COVID-19. The direct 371 correlation with soluble PDL-1 is also relevant, since this the ligand of the inhibitory 372 co-receptor PD1 on T cells, which activation induces anergy of T lymphocytes [29]. This 373 finding reinforces the potential role of immune checkpoint inhibitors in severe COVID-19 374 [30]. In turn, the association found between viral RNA load in plasma and three mediators 375 of endothelial dysfunction (VCAM-1, angiopoietin 2 and ICAM-1), and with coagulation 376 activation markers (D-dimers and INR prolongation) suggests a potential virally linked 377 mechanism in the pathogenesis of endothelitis and thrombosis in COVID-19 disease [7]. 378 Finally, the correlation with the acute phase reactants CRP and ferritin suggests a 379 connection between shedding of genomic material of the virus to the blood and the 380 induction of a systemic inflammatory response which is observed in those patients needing 381 critical care.

382 The strongest inverse correlations found in our study was between SARS-CoV-2 RNA

383 load in plasma and lymphocyte and monocyte counts in peripheral blood, for which

384 critically ill patients showed the lowest values. Active viral replication could be a

385 precipitating event in the pathogenesis of lymphopenia and monocytopenia in severe

386 COVID-19 patients [11] [31], by mediating direct cytopathic actions or stimulating the

387 migration of these cells to the extravascular space to reach the infected tissues [32].

388 A limitation of our work is its observational nature, which precludes to infer causality.

389 Nonetheless, the observed associations could serve as hypothesis generators, leading to the

390 development of animal models to confirm the potential link between SARS-CoV-2

391 replication and the dysregulated host responses observed in severe COVID-19.

392 Conclusion:

393 Presence of SARS-CoV-2 RNA in plasma is associated with critical illness in patients with

394 COVID-19. The strength of this association increases with viral RNA load in plasma,

395 which in turn correlates with key signatures of dysregulated host response in COVID-19

396 (figure 5). Our findings suggest a major role of uncontrolled viral replication in the

397 pathogenesis of this disease. Assessment of viral RNAemia and viral RNA load in plasma

398 could be useful to early detect those patients at risk of clinical deterioration, to assess

399 response to treatment and to predict disease outcome.

400 List of abbreviations

401 SARS-CoV-2: Severe acute Respiratory Syndrom-Coronavirus-2

402 LDH: Lactate dehydrogenase

403 G-CSF: Granulocyte colony-stimulating factor

404 TLR: toll like receptor

406 Ethics approval and consent to participate: The study was approved by the Committee 407 for Ethical Research of the coordinating institution, "Comite de Etica de la Investigacion 408 con Medicamentos del Area de Salud de Salamanca", code PI 2020 03 452. Informed 409 consent was obtained orally when clinically possible. In the remaining cases, the informed 410 consent waiver was authorized by the Ethics committee.

411 Consent for publication: not applicable

412 Availability of data and materials: the datasets generated and/or analysed during the 413 current study are not publicly available since they are still under elaboration for publication 414 by the authors but are available from the corresponding author on reasonable request.

415 Competing interests

416 The authors declare that they have no competing interests

417 Funding

418 This work was supported by awards from the Canadian Institutes of Health Research, the 419 Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding initiative (CIHR 420 OV2 – 170357), Research Nova Scotia (DJK), Atlantic Genome/Genome Canada (DJK), 421 Li-Ka Shing Foundation (DJK), Dalhousie Medical Research Foundation (DJK), the 422 "Subvenciones de concesión directa para proyectos y programas de investigación del virus 423 SARS-CoV2, causante del COVID-19", FONDO - COVID19, Instituto de Salud Carlos III 424 (COV20/00110, CIBERES, 06/06/0028), (AT) and finally by the "Convocatoria 425 extraordinaria y urgente de la Gerencia Regional de Salud de Castilla y León, para la 426 financiación de proyectos de investigación en enfermedad COVID-19" (GRS COVID 427 53/A/20) (CA). DJK is a recipient of the Canada Research Chair in Translational

428 Vaccinology and Inflammation. APT was funded by the Sara Borrell Research Grant 429 CD018/0123 funded by Instituto de Salud Carlos III and co-financed by the European 430 Development Regional Fund (A Way to Achieve Europe programme). The funding sources 431 did not play any role neither in the design of the study and collection, not in the analysis, in 432 the interpretation of data or in writing the manuscript.

433 Authors 'contribution: JFBM, DJK, JB, RF, FB, AT and RM designed the study. JFBM 434 and DJK wrote the manuscript and interpreted the data. RA coordinated the clinical study 435 and drafted the figures. MGR, DM, PR, FPG, LT, RLI, EB, CA, JMG, JR, RM, MIF, GM, 436 MGE, DC, FDC, JFR, WT, PGJ, GR, IM, EG, IM, SP, SM, PGO, JAC, TRA, CP, JAB, 437 GR, RH, JB, PE, RC, JA, JGB, NM, NBL, LJV, BFC, MAM recruited the patients and /or 438 collected the clinical data. MDG, AO, RO, LMR and JME performed the assays for the 439 detection of SARS-CoV-2 IgG and viremia. APT, CD and AO developed the ddPCR 440 works; CD and NJ profiled the immunological mediators. SR, AMF and MMF developed 441 the statistical analysis and drafted the figures. AAK, ATO, AM and LF performed the 442 literature search. All authors read and approved the final manuscript.

444 Ackowledgements: we thank SEIMC-GESIDA Foundation for the scientific sponsoring of 445 this project. We thank also the "Biobanco del Centro de Hemoterapia y Hemodonación de 446 Castilla y León", which provided the plasma simples used in the healthy control group.

443

447

448

449

References:

- 452 1. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at
- 453 Johns Hopkins University (JHU) [Internet]. Available from:
- https://coronavirus.jhu.edu/map.html 454
- 455 2. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics
- of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 456
- 457 3. Cevik M, Bamford CGG, Ho A. COVID-19 pandemic—a focused review for
- clinicians. Clinical Microbiology and Infection. Elsevier; 2020;26:842–7. 458
- 4. Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, Hu B, et al. Molecular and 459
- serological investigation of 2019-nCoV infected patients: implication of multiple 460
- 461 shedding routes. Emerging Microbes & Infections. Taylor & Francis; 2020;9:386–9.
- 462 5. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable Serum Severe
- Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely 463
- Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With 464
- 465 Coronavirus Disease 2019. Clin Infect Dis [Internet]. [cited 2020 Jul 6]; Available
- 466 from: https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa449/5821311
- 6. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease 467
- severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-468
- 469 March 2020: retrospective cohort study. BMJ. 2020;369:m1443.
- 470 7. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al.
- 471 Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–8.
- 8. Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis: 472
- 473 observations and hypotheses. Lancet. 2020;395:1517–20.
- 474 9. Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine
- elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, 475
- 476 and comparison with other inflammatory syndromes. The Lancet Respiratory Medicine
- [Internet]. Elsevier; 2020 [cited 2020 Oct 21];0. Available from: 477
- https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30404-5/abstract 478
- 10. Laing AG, Lorenc A, Del Molino Del Barrio I, Das A, Fish M, Monin L, et al. A 479
- 480 dynamic COVID-19 immune signature includes associations with poor prognosis. Nat
- Med. 2020; 481
- 11. Bao J, Li C, Zhang K, Kang H, Chen W, Gu B. Comparative analysis of laboratory 482
- 483 indexes of severe and non-severe patients infected with COVID-19. Clin Chim Acta.
- 484 2020;509:180-94.
- 485 12. Hupf J, Mustroph J, Hanses F, Evert K, Maier LS, Jungbauer CG. RNA-expression
- 486 of adrenomedullin is increased in patients with severe COVID-19. Crit Care.
- 2020;24:527. 487

- 13. McGonagle D, O'Donnell JS, Sharif K, Emery P, Bridgewood C. Immune 488
- mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet 489
- 490 Rheumatol. 2020;2:e437-45.
- 491 14. Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19:
- 492 immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther.
- 493 2020;5:128.
- 15. Hogan CA, Stevens BA, Sahoo MK, Huang C, Garamani N, Gombar S, et al. High 494
- 495 Frequency of SARS-CoV-2 RNAemia and Association With Severe Disease. Clin
- Infect Dis. 2020; 496
- 16. Veyer D, Kernéis S, Poulet G, Wack M, Robillard N, Taly V, et al. Highly sensitive 497
- quantification of plasma SARS-CoV-2 RNA shelds light on its potential clinical value. 498
- 499 Clin Infect Dis. 2020;
- 17. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of 500
- COVID-19: Current State of the Science. Immunity. 2020;52:910–41. 501
- 502 18. Cameron MJ, Ran L, Xu L, Danesh A, Bermejo-Martin JF, Cameron CM, et al.
- 503 Interferon-mediated immunopathological events are associated with atypical innate and
- 504 adaptive immune responses in patients with severe acute respiratory syndrome. J Virol.
- 505 2007;81:8692–706.
- 19. Cameron MJ, Bermejo-Martin JF, Danesh A, Muller MP, Kelvin DJ. Human 506
- 507 immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res.
- 508 2008;133:13-9.
- 20. Bermejo-Martin JF, Ortiz de Lejarazu R, Pumarola T, Rello J, Almansa R, Ramírez 509
- 510 P, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe
- pandemic influenza. Crit Care. 2009;13:R201. 511
- 21. Rubio I, Osuchowski MF, Shankar-Hari M, Skirecki T, Winkler MS, Lachmann G, 512
- 513 et al. Current gaps in sepsis immunology: new opportunities for translational research.
- 514 Lancet Infect Dis. 2019;19:e422-36.
- 515 22. CDC. Information for Laboratories about Coronavirus (COVID-19) [Internet].
- Centers for Disease Control and Prevention. 2020 [cited 2020 Oct 14]. Available from: 516
- 517 https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html
- 23. Hagman K, Hedenstierna M, Gille-Johnson P, Hammas B, Grabbe M, Dillner J, et 518
- 519 al. SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a
- 520 retrospective cohort study. Clin Infect Dis. 2020;
- 24. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJD, Chau TNB, et al. 521
- Fatal outcome of human influenza A (H5N1) is associated with high viral load and 522
- 523 hypercytokinemia. Nat Med. 2006;12:1203-7.
- 25. Almansa R, Anton A, Ramirez P, Martin-Loeches I, Banner D, Pumarola T, et al. 524
- 525 Direct association between pharyngeal viral secretion and host cytokine response in
- severe pandemic influenza. BMC Infect Dis. 2011;11:232. 526

- 26. Birra D, Benucci M, Landolfi L, Merchionda A, Loi G, Amato P, et al. COVID 19:
- a clue from innate immunity. Immunol Res. 2020;68:161–8.
- 529 27. Perera P-Y, Lichy JH, Waldmann TA, Perera LP. The role of interleukin-15 in
- inflammation and immune responses to infection: implications for its therapeutic use.
- 531 Microbes Infect. 2012;14:247–61.
- 532 28. Sugamata R, Dobashi H, Nagao T, Yamamoto K-I, Nakajima N, Sato Y, et al.
- Contribution of neutrophil-derived myeloperoxidase in the early phase of fulminant
- acute respiratory distress syndrome induced by influenza virus infection. Microbiol
- 535 Immunol. 2012;56:171–82.
- 536 29. Venet F, Monneret G. Advances in the understanding and treatment of sepsis-
- induced immunosuppression. Nat Rev Nephrol. 2018;14:121–37.
- 30. Remy KE, Brakenridge SC, Francois B, Daix T, Deutschman CS, Monneret G, et al.
- Immunotherapies for COVID-19: lessons learned from sepsis. Lancet Respir Med.
- 540 2020;

548

549

- 31. Bermejo-Martin JF, Almansa R, Menendez R, Mendez R, Kelvin DJ, Torres A.
- Lymphopenic community acquired pneumonia as signature of severe COVID-19.
- Journal of Infection. 2020;
- 32. Monneret G, Cour M, Viel S, Venet F, Argaud L. Coronavirus disease 2019 as a
- particular sepsis: a 2-week follow-up of standard immunological parameters in critically
- ill patients. Intensive Care Med. 2020;46:1764–5.

- 550 **Conflicts of interests:** the authors declare no conflicts of interests regarding this
- 551 submission

| | | Outpatients (1) | Ward (2) | ICU (3) | p value (1 vs 2) | <i>p</i> value (1 vs 3) | <i>p</i> value (2 vs 3) |
|------------------|---|-----------------|-------------|---------------|------------------|-------------------------|-------------------------|
| Chamadadia | Age [years, median (IQR)] | 48.50 [19] | 64 [20] | 66 [19] | < 0.001 | < 0.001 | n.s. |
| Characteristics | Male [%, (n)] | 46 (23) | 50 (50) | 64 (64) | n.s. | 0.035 | 0.046 |
| | Alcoholism | 2 (1) | 0 (0) | 1 (1) | n.s. | n.s. | n.s. |
| | Smoking | 4 (2) | 5 (5) | 6 (6) | n.s. | n.s. | n.s. |
| | Drug abuse | 2 (1) | 0 (0) | 0 (0) | n.s. | n.s. | n.a. |
| | Cardiac disease | 4 (2) | 13 (13) | 9 (9) | n.s. | n.s. | n.s. |
| | Chronic vascular disease | 2 (1) | 2 (2) | 5 (5) | n.s. | n.s. | n.s. |
| | COPD | 2 (1) | 2 (2) | 3 (3) | n.s. | n.s. | n.s. |
| | Asthma | 8 (4) | 6 (6) | 2 (2) | n.s. | n.s. | n.s. |
| | Obesity | 4 (2) | 26 (26) | 26 (26) | 0.001 | 0.001 | n.s. |
| | Hypertension | 24 (12) | 44 (44) | 45 (45) | 0.017 | 0.012 | n.s. |
| Comorbidities, | Dyslipidemia | 16 (8) | 41 (41) | 34 (34) | 0.002 | 0.021 | n.s. |
| [% (n)] | Chronic renal disease | 2(1) | 3 (3) | 3 (3) | n.s. | n.s. | n.s. |
| | Chronic hepatic disease | 2 (1) | 0 (0) | 3 (3) | n.s. | n.s. | n.s. |
| | Neurological disease | 0 (0) | 6 (6) | 3 (3) | n.s. | n.s. | n.s. |
| | HIV | 0 (0) | 0 (0) | 1 (1) | n.a. | n.s. | n.s. |
| | Autoimmune disease | 2 (1) | 1 (1) | 1 (1) | n.s. | n.s. | n.s. |
| | Chronic inflammatory bowel disease | 0 (0) | 2 (2) | 1 (1) | n.s. | n.s. | n.s. |
| | Type 1 diabetes | 0 (0) | 0 (0) | 3 (3) | n.a. | n.s. | n.s. |
| | Type 2 diabetes | 0 (0) | 23 (23) | 22 (22) | < 0.001 | < 0.001 | n.s. |
| | Cancer | 6 (3) | 2 (2) | 1 (1) | n.s. | n.s. | n.s. |
| | Invasive mechanical ventilation | 0 (0) | 0 (0) | 96 (96) | n.a. | < 0.001 | < 0.001 |
| | Non-invasive mechanical ventilation | 0 (0) | 14 (14) | 34 (34) 0.004 | | < 0.001 | 0.002 |
| | Hydroxychloroquine | 77.6 (38) | 89 (89) | 99 (99) n.s. | | < 0.001 | 0.003 |
| Treatment during | Chloroquine | 4.1 (2) | 7 (7) | 0 (0) n.s. | | 0.042 | 0.007 |
| hospitalization, | Corticoids | 6.7 (3) | 29 (29) | 85 (85) | 0.002 | < 0.001 | < 0.001 |
| [% (n)] | Azithromycin | 15.9 (7) | 84 (84) | 84 (84) | < 0.001 | < 0.001 | n.s. |
| | Remdesivir | 0 (0) | 1 (1) | 9 (9) | n.s. | 0.029 | 0.009 |
| | Tocilizumab | 0 (0) | 13 (13) | 33 (33) | 0.008 | < 0.001 | 0.001 |
| | Lopinavir/ritonavir | 74 (37) | 35 (35) | 96 (96) | < 0.001 | < 0.001 | < 0.001 |
| | Beta Interferon | 0 (0) | 0 (0) | 55 (55) | n.a. | < 0.001 | < 0.001 |
| | Hospital stay [days, median, (IQR)] | - | 9 (6) | 24 (19) | n.a. | n.a. | < 0.001 |
| | Viral RNAemia [% (n)] | 2 (1) | 27 (27) | 78 (78) | < 0.001 | < 0.001 | < 0.001 |
| Time course and | Viral RNA load in plasma (N1) (copies / mL, median, (IQR)) | 0 (0) | 0 (91) | 829 (4444) | n.s. | < 0.001 | < 0.001 |
| outcome | Viral RNA load in plasma (N2) (copies / mL, median, (IQR)) | 0 (0) | 0 (93) | 836 (4939) | n.s. | < 0.001 | < 0.001 |
| | SARS-CoV-2 IgG, [% (n)] | 52 (26) | 49 (49) | 70 (70) | n.s. | 0.030 | 0.002 |
| | Hospital mortality, [% (n)] | 0 (0) | 0 (0) | 49(49) | n.a. | < 0.001 | < 0.001 |
| | Temperature (°C) [median (IQR)] | 36.50 (1.0) | 36.80 (1.4) | 37.00 (1.4) | - | - | - |
| | Systolic Pressure (mmHg) [median (IQR)] | 120 (29) | 126 (25) | 120 (26) | n.s. | n.s. | 0.001 |
| | Oxygen saturation (%) [median (IQR)] | 96 (3) | 94 (5) | 92 (6) | 0.002 | < 0.001 | 0.002 |

93 (93)

67 (67)

112 (31)

0.91 (0.33)

138 (5)

4.10 (0.68)

207 [113]

1.11 (0.13)

1597362

[2024704]

278 (138)

29 (29)

523805

100 (100)

93 (93)

160.50 (83)

0.88 (0.57)

138.50 (7)

3.95 (0.90)

204 [126]

1.22 (0.22)

6182104

[52690922]

496 (285)

44 (44.50)

923687

72 (36)

26 (13)

99.5 (22)

0.84 (0.18)

138 (4)

3.90 (0.50)

223 [97]

1.04 (0.10)

795278

[828234]

214 (73)

27 (43)

359507

Pulmonary infiltrate [% (n)]

Bilateral pulmonary infiltrate [% (n)]

Glucose (mg/dl) [median (IQR)]

Creatinine (mg/dl) [median (IQR)]

Na (mEq/L) [median (IQR)]

K (mEq/L) [median (IQR)]

Platelets (cell x 10 3/ µl) [median (IQR)]

INR [median (IQR)]

D Dimer (pg/ml) [median (IQR)]

LDH (UI/L) [median (IQR)]

GPT (UI/L) [median (IQR)]

Ferritin (pg/ml) [median (IQR)]

| | 24 | |
|---------|---------|---------|
| | | |
| < 0.001 | < 0.001 | 0.007 |
| < 0.001 | < 0.001 | < 0.001 |
| < 0.001 | < 0.001 | < 0.001 |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| 0.004 | < 0.001 | < 0.001 |
| < 0.001 | < 0.001 | < 0.001 |
| 0.002 | < 0.001 | < 0.001 |

0.021

< 0.001

n.s.

0.001

0.002

2/

Measurements at diagnosis

553

554

555

556

557

558

559

560

561

562

563

Measurements at diagnosis

[458748] [534757] [1526492] CRP (mg/dl) [median (IQR)] 1.40 (3.50) 40.90 (89.18) 91 (182.10) < 0.001 < 0.001 0.031 38.15 (6.48) Haematocrit (%) [median (IQR)] 42.50 (6.50) < 0.001 < 0.001 43.15 (4.72) n.s. WBC (cells/mm3) [median (IQR)] 6450 (2815) 7005 (4115) 9145 (6613) < 0.001 0.006 n.s. Lymphocytes (cells/mm3) 1400 (805) 1000 (433) 540 (445) 0.006 < 0.001 < 0.001 [median (IQR)] Neutrophils (cells/mm3) 4260 (2625) 5250 (3918) 8300 (5880) < 0.001 < 0.001 n.s [median (IQR)] Monocytes (cells/mm3) 500 (300) 400 (300) < 0.001 300 (280) < 0.001 n.s. [median (IQR)]

Table 1: Clinical characteristics of the patients: continuous variables are represented as [median, (interquartile range, IQR)]; categorical variables are represented as [%, (n)].; INR, International Normalized Ratio; n.s., not significant; n.a., not applicable. COPD (Chronic obstructive pulmonary disease), HIV (Human Immunodeficiency Virus), INR (International Normalized Ratio), LDH (Lactic Acid Dehydrogenase), GPT (glutamic-pyruvate transaminase); CRP (C-reactive protein), WBC (white blood cell).

| | OR [CI95%] | p | OR [CI95%] | p | OR [CI95%] | p |
|---|------------------------|-------|------------------------|-------|------------------------|-------|
| Sex (male) | 2.055 [0.656 - 6.432 | 0.216 | 1.647 [0.508 - 5.337] | 0.406 | 1.608 [0.500 - 5.166] | 0.425 |
| Systolic Pressure (mmHg) | 0.985 [0.960 - 1.011 | 0.253 | 0.984 [0.958 - 1.011] | 0.247 | 0.984 [0.957 - 1.012] | 0.261 |
| O2 Saturation (%) | 1.069 [0.986 - 1.160] | 0.107 | 1.076 [0.992 - 1.167] | 0.079 | 1.082 [0.993 - 1.180] | 0.071 |
| Bilateral pulmonary infiltrate | 2.343 [0.469 - 11.707] | 0.300 | 3.088 [0.566 - 16.852] | 0.193 | 3.064 [0.539 - 17.430] | 0.207 |
| Glucose (mg/dl) | 1.008 [1.001 - 1.015] | 0.028 | 1.007 [1.000 - 1.015] | 0.061 | 1.007 [0.999 - 1.014] | 0.070 |
| INR | 1.123 [0.433 - 2.915] | 0.812 | 1.245 [0.469 - 3.305] | 0.661 | 1.377 [0.519 - 3.657] | 0.521 |
| D-dimer (pg/mL) | 1.000 [1.000 - 1.000] | 0.294 | 1.000 [1.000 - 1.000] | 0.190 | 1.000 [1.000 - 1.000] | 0.420 |
| LDH (UI/L) | 1.009 [1.004 - 1.014] | 0.000 | 1.008 [1.003 - 1.013] | 0.002 | 1.009 [1.004 - 1.014] | 0.001 |
| GPT (UI/L) | 1.005 [0.992 - 1.019] | 0.443 | 1.005 [0.991 - 1.019] | 0.516 | 1.006 [0.992 - 1.021] | 0.402 |
| Ferritin (pg/mL) | 1.000 [1.000 - 1.000] | 0.705 | 1.000 [1.000 - 1.000] | 0.856 | 1.000 [1.000 - 1.000] | 0.835 |
| CRP (mg/dl) | 0.998 [0.992 - 1.003] | 0.420 | 0.999 [0.993 - 1.005] | 0.749 | 0.998 [0.993 - 1.004] | 0.547 |
| Haematocrit (%) | 0.770 [0.676 - 0.877] | 0.000 | 0.762 [0.665 - 0.872] | 0.000 | 0.737 [0.633 - 0.858] | 0.000 |
| SARS-CoV-2 IgG (Yes) | 1.967 [0.627 -6.170] | 0.246 | 1.835 [0.562 - 5.987] | 0.315 | 1.918 [0.577 - 6.377] | 0.288 |
| Lymphocytes (cells/mm3) | 0.998 [0.996 - 1.000] | 0.011 | 0.998 [0.996 - 1.000] | 0.012 | 0.998 [0.996 - 0.999] | 0.010 |
| Monocytes (cells/mm3) | 0.998 [0.995 - 1.001] | 0.180 | 0.998 [0.995 - 1.001] | 0.212 | 0.999 [0.996 - 1.002] | 0.463 |
| Neutrophils (cells/mm3) | 1.000 [1.000 - 1.000] | 0.262 | 1.000 [1.000 - 1.000] | 0.326 | 1.000 [1.000 - 1.000] | 0.239 |
| Viral RNAemia (Yes) | 3.916 [1.183 - 12.968] | 0.025 | - | - | - | - |
| Viral RNA load (N1) in plasma, log (copies/mL) | - | - | 1.962 [1.244 - 3.096] | 0.004 | - | - |
| Viral RNA load (N2) in plasma, log (copies/mL) | - | - | - | - | 2.229 [1.382 - 3.595] | 0.001 |

Table 2: Multivariate logistic regression analysis comparing wards patients against critically ill patients (Enter method). The association between viral RNAemia or viral RNA load targeting the N1 region, or viral RNA load targeting the N2 region with critical illness was evaluated adjusting by major confounding factors.






Figure 1: Viral RNA load in plasma, targeting the N1 region (left) and the N2 region (right), in the three groups of patients. Results are provided as copies of cDNA per mL of plasma.






Figure 2. Heat map representing the Spearman correlation coefficients between viral RNA load in plasma targeting the N1 and the N2 regions and representative indicators of host dysregulated response.




Figure 3. Levels of laboratory parameters indicating host dysregulated response across groups. † indicates significant difference with the healthy control and the bars significant differences between the other groups.

602




Figure 4: Levels of laboratory parameters indicating host dysregulated response across groups. † indicates significant difference with the healthy control and the bars significant differences between the other groups.

607




Figure 5: Integrative model depicting the correlations found between the

indicators of host dysregulated responses and SARS-CoV-2 RNA load in plasma.

| Hospital | Outpatients | Wards | ICU |
|--------------------------------------|-------------|-------|-----|
| Hospital Clínico Universitario de | | | |
| Valladolid | 0 | 0 | 45 |
| Hospital General Universitario | | | |
| Gregorio Marañón (Madrid) | 44 | 4 | 25 |
| Hospital Universitario Infanta | | | |
| Leonor (Madrid) | 0 | 30 | 0 |
| Hospital Universitario y Politécnico | | | |
| de La Fe (Valencia) | 0 | 27 | 0 |
| Hospital Universitario Rio Hortega | | | |
| (Valladolid) | 2 | 22 | 23 |
| Hospital Universitario Príncipe de | | | |
| Asturias (Madrid) | 4 | 17 | 1 |
| Hospital Universitario de Burgos | 0 | 0 | 2 |
| Hospital Universitario de León | 0 | 0 | 4 |
| Total | 50 | 100 | 100 |

Additional file 1: recruited patients in each hospital

| | OR [CI 95%] | р |
|-------------------------|------------------------|-------|
| Age (years) | 1.071 [1.024 - 1.121] | 0.003 |
| Obesity | 5.618 [0.841 - 37.552] | 0.075 |
| Hypertension | 1.024 [0.279 - 3.756] | 0.972 |
| Dyslipidemia | 1.521 [0.354 - 6.532] | 0.573 |
| O2 saturation | 1.077 [0.946 - 1.226] | 0.261 |
| Bilateral infiltrate | 7.652 [2.050 - 28.558] | 0.002 |
| Glucose (mg/dl) | 1.022 [0.992 - 1.054] | 0.156 |
| INR | 3.346 [0.121 - 92.829] | 0.476 |
| D Dimer (pg/ml) | 1.000 [1.000 - 1.000] | 0.111 |
| LDH (UI/L) | 1.005 [0.998 - 1.012] | 0.176 |
| CRP (mg/dl) | 1.032 [1.012 - 1.052] | 0.002 |
| Lymphocytes (cells/mm3) | 1.000 [0.998 - 1.001] | 0.440 |
| Monocytes (cells/mm3) | 0.998 [0.996 - 1.001] | 0.223 |
| Neutrophils (cells/mm3) | 1.000 [1.000 - 1.000] | 0.382 |
| Viral RNAemia | 3.793 [0.344 - 41.845] | 0.277 |

Additional file 2. Multivariate logistic regression analysis comparing outpatients against wards patients (Enter method). The association between viral RNAemia with hospitalization at the wards was evaluated adjusting by major confounding factors.

| | OR [CI95%] | р |
|-----------------------|------------------------|-------|
| Age | 1.057 [1.017 - 1.098] | 0.005 |
| Obesity | 6.675 [1.129 - 39.472] | 0.036 |
| Bilateral infiltrate | 6.400 [2.153 - 19.024] | 0.001 |
| Glucose (mg/dl) | 1.027 [0.999 - 1.055] | 0.058 |
| CRP (mg/dl) | 1.032 [1.013 -1.051] | 0.001 |
| Monocytes (cells/mm3) | 0.997 [0.995 - 1.000] | 0.017 |

663

664

665

666

667

Additional file 3. Multivariate logistic regression analysis comparing outpatients against wards patients (backward stepwise selection method / Likelihood Ratio). The association between viral RNAemia with hospitalization at the wards was evaluated adjusting by major confounding factors, but it was not selected in the final model.

| | OR [CI95%] | | р | OR [CI95%] | | р | OR [CI95%] | | р | | | |
|---|------------|-------|--------|------------|-------|-------|------------|-------|-------|-------|-------|-------|
| Systolic Pressure (mmHg) | 0.976 | 0.953 | 1.000 | 0.049 | 0.974 | 0.949 | 0.999 | 0.040 | 0.974 | 0.950 | 0.999 | 0.042 |
| Glucose (mg/dl) | 1.006 | 1.000 | 1.012 | 0.050 | 1.006 | 1.000 | 1.012 | 0.055 | 1.005 | 0.999 | 1.012 | 0.088 |
| D-dimer (pg/mL) | 1.000 | 1.000 | 1.000 | 0.057 | 1.000 | 1.000 | 1.000 | 0.025 | 1.000 | 1.000 | 1.000 | 0.088 |
| LDH (UI/L) | 1.008 | 1.004 | 1.011 | 0.000 | 1.006 | 1.003 | 1.010 | 0.001 | 1.007 | 1.004 | 1.011 | 0.000 |
| Haematocrit (%) | 0.798 | 0.717 | 0.888 | 0.000 | 0.789 | 0.706 | 0.881 | 0.000 | 0.775 | 0.688 | 0.873 | 0.000 |
| Lymphocytes (cells/mm3) | 0.997 | 0.996 | 0.999 | 0.000 | 0.997 | 0.996 | 0.999 | 0.000 | 0.997 | 0.996 | 0.999 | 0.000 |
| Viral RNAemia (Yes) | 4.270 | 1.575 | 11.580 | 0.004 | | | | | | | | |
| Viral RNA load (N1) in plasma, log (copies/mL) | | | | | 2.005 | 1.350 | 2.978 | 0.001 | | | | |
| Viral RNA load (N2) in plasma, log (copies/mL) | | | | | | | | | 2.071 | 1.419 | 3.022 | 0.000 |

Additional file 4. Multivariate logistic regression analysis comparing wards patients against ICU patients (backward stepwise selection method / Likelihood Ratio). The association between viral RNAemia and viral RNA load with critical illness was evaluated adjusting by major confounding factors.

| preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity All rights reserved. No reuse allowed without permission. | | | | | | | | | | |
|--|----------------------------|-------------------------|-----------------------|--------------------------|---------------|---------------|------------|---------------|---------------|---------------|
| | Healthy Controls (0) | Outpatients (1) | Ward (2) | ICU (3) | p (0 vs 1) | p (0 vs 2) | p (0 vs 3) | p (1 vs 2) | p (1 vs 3) | p (2 vs 3) |
| ICAM-1 (pg/ml) | 289208 [92857] | 358431.50 [88702.30] | 377655 [150081.80] | 466818 [202189.80] | 0.036 | < 0.001 | < 0.001 | n.s. | < 0.001 | < 0.001 |
| Lipocalin-2 (pg/ml) | 82634.50 [29205.30] | 73134.50 [32007.30] | 94077 [49868] | 100165 [57819.80] | n.s. | n.s. | n.s. | 0.011 | < 0.001 | n.s. |
| Myeloperoxidase (pg/ml) | 27541.50 [12906.80] | 41902 [30413.80] | 88244.50 [78145] | 141971.50 [148623.50] | n.s. | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| VCAM-1 (pg/ml) | 618380 [195510.50] | 800393 [403378] | 1191387 [618827] | 1248699.50 [603679] | 0.021 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | n.s. |
| PD-L1 (pg/ml) | 55.85 [33.27] | 110.50 [120.68] | 178 [114.25] | 228 [137.75] | 0.031 | < 0.001 | < 0.001 | 0.045 | < 0.001 | 0.031 |
| G-CSF (pg/ml) | 6.90 [7.67] | 23.55 [20.48] | 31.95 [42.85] | 36.25 [53.35] | < 0.001 | < 0.001 | < 0.001 | n.s. | 0.022 | n.s. |
| IL-1b (pg/ml) | 0.44 [1.65] | 0.16 [0.30] | 0.44 [0.53] | 0.38 [0.51] | n.s. | n.s. | n.s. | 0.005 | < 0.001 | n.s. |
| IL-10 (pg/ml) | 1.59 [0.48] | 4.19 [6.68] | 9.11 [10.14] | 17 [22.25] | 0.002 | < 0.001 | < 0.001 | 0.007 | < 0.001 | < 0.001 |
| IL-17A (pg/ml) | 1.95 [1.08] | 2.38 [1.45] | 2.32 [1.44] | 3.06 [2.87] | n.s. | 0.047 | 0.002 | n.s. | n.s. | n.s. |
| GM-CSF (pg/ml) | 0.66 [0.42] | 1.07 [0.54] | 1.10 [0.67] | 1.62 [1.01] | n.s. | n.s. | < 0.001 | n.s. | < 0.001 | < 0.001 |
| IL-7 (pg/ml) | 1.81 [1.49] | 2.04 [3.12] | 3.19 [4.19] | 4.84 [5.17] | n.s. | 0.009 | < 0.001 | 0.017 | < 0.001 | n.s. |
| CXCL10 (pg/ml) | 91.9 [71.85] | 470.50 [731.50] | 977.50 [943] | 1609.50 [1693.75] | 0.003 | < 0.001 | < 0.001 | 0.002 | < 0.001 | 0.003 |
| Angiopoietin-2 (pg/ml) | 708 [260.75] | 809 [479.75] | 1128 [779.50] | 1769.50 [2064.25] | n.s. | 0.001 | < 0.001 | 0.008 | < 0.001 | 0.001 |
| IL-1ra (pg/ml) | 478 [1159.75] | 653.50 [1039.25] | 1796 [1896] | 1634 [4472.50] | n.s. | < 0.001 | < 0.001 | < 0.001 | < 0.001 | n.s |
| IL-6 (pg/ml) | 1.27 [0.83] | 6.34 [12.42] | 33.25 [48.10] | 105.50 [252.23] | 0.027 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| CCL2 (pg/ml) | 103.50 [39] | 189 [157.50] | 283.50 [304] | 490 [881.75] | 0.012 | < 0.001 | < 0.001 | 0.031 | < 0.001 | < 0.001 |
| IL-12p70 (pg/ml) | 0.62 [0.71] | 1.46 [0.67] | 1.51 [0.71] | 1.36 [0.94] | < 0.001 | < 0.001 | < 0.001 | n.s. | n.s. | n.s. |
| IL-2 (pg/ml) | 0.02 [0.09] | 0.53 [0.39] | 0.49 [0.57] | 0.63 [0.83] | < 0.001 | < 0.001 | < 0.001 | n.s. | n.s. | n.s. |
| IL-4 (pg/ml) | 0.13 [0.27] | 0.33 [0.34] | 0.33 [0.39] | 0.29 [0.37] | 0.021 | 0.006 | 0.041 | n.s. | n.s. | n.s. |
| IL-15 (pg/ml) | 2.11 [0.54] | 3.85 [3.7] | 4.89 [2.90] | 8.38 [5.19] | 0.001 | < 0.001 | < 0.001 | n.s. | < 0.001 | < 0.001 |
| Granzyme-B (pg/ml) | 12 [15.75] | 33.20 [27.92] | 46.15 [40.03] | 39.25 [35.58] | < 0.001 | < 0.001 | < 0.001 | n.s. | n.s. | 0.036 |
| INFγ (pg/ml) | 0.68 [0.45] | 4.35 [14.16] | 7.42 [15.13] | 3.44 [8.50] | < 0.001 | < 0.001 | < 0.001 | n.s. | n.s. | 0.021 |

| TNFα (pg/ml) | 5.11 [1.79] | 10.60 [4.18] | 13 [6.46] | 12.95 [10.34] | < 0.001 | < 0.001 | < 0.001 | 0.021 | 0.006 | n.s. |
|-----------------|----------------|-----------------|--------------|------------------|---------|---------|---------|-------|-------|------|
| 691 | | | | l | | | | | | |

Additional file 5. Laboratory parameters 'levels across groups. 692